A Phase I Study to Evaluate the Tolerability and Safety of LC002, a DermaVir Vaccine, in HIV-1-Infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART).
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2013
At a glance
- Drugs LC 002 (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 18 May 2012 Results published in PLoS ONE, as reported in a Genetic Immunity media release.
- 12 Feb 2008 New trial record.